Novel biological activity of ameloblastin in enamel matrix derivative

Kuramitsu-Fujimoto, Sachiko; Ariyoshi, Wataru; Saito, Noriko; Okinaga, Toshinori; Kamo, Masaharu; Ishisaki, Akira; Takata, Takashi; Yamaguchi, Kazunori; Nishihara, Tatsuji

doi:10.1590/1678-775720140291

Cited by 4 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of AMBN in adipocytes seem analogous to effects previously reported in non-mineralizing ameloblasts, e.g. both cell types express a short AMBN splice variant, a translated AMBN C-terminus variant (Lee et al., 2003; Ravindranath et al., 2007), and administration of rAMBN reduce proliferation (Fukumoto et al., 2004; Fukumoto et al., 2005; Kuramitsu-Fujimoto et al., 2015; Sonoda et al., 2009; Y. B. Zhang et al., 2011).…”

Section: Discussionsupporting

confidence: 70%

An ameloblastin C-terminus variant is present in human adipose tissue

Stakkestad

Heyward

Lyngstadaas

et al. 2018

Heliyon

View full text Add to dashboard Cite

ObjectiveTranscriptional regulatory elements in the ameloblastin (AMBN) promoter indicate that adipogenesis may influence its expression. The objective here was to investigate if AMBN is expressed in adipose tissue, and have a role during differentiation of adipocytes.DesignAMBN expression was examined in adipose tissue and adipocytes by real-time PCR and ELISA. Distribution of ameloblastin was investigated by immunofluorescence in sections of human subcutaneous adipose tissue. The effect of recombinant proteins resembling AMBN and its processed products on proliferation of primary human pre-adipocytes and murine 3T3-L1 cell lines was measured by [3H]-thymidine incorporation. The effect on adipocyte differentiation was evaluated by the expression profile of the adipogenic markers PPARγ and leptin, and the content of lipids droplets (Oil-Red-O staining).ResultsAMBN was found to be expressed in human adipose tissue, human primary adipocytes, and in 3T3-L1 cells. The C-terminus of the AMBN protein and a 45 bp shorter splice variant was identified in human subcutaneous adipose tissue. The expression of AMBN was found to increase four-fold during differentiation of 3T3-L1 cells. Administration of recombinant AMBN reduced the proliferation, and enhanced the expression of PPARγ and leptin in 3T3-L1 and human pre-adipocytes, respectively.ConclusionsThe AMBN C-terminus variant was identified in adipocytes. This variant may be encoded from a short splice variant. Increased expression of AMBN during adipogenesis and its effect on adipogenic factors suggests that AMBN also has a role in adipocyte development.

show abstract

Section: Discussionsupporting

confidence: 70%

An ameloblastin C-terminus variant is present in human adipose tissue

Stakkestad

Heyward

Lyngstadaas

et al. 2018

Heliyon

View full text Add to dashboard Cite

show abstract

“…In addition, a previous study demonstrated that recombinant AMEL inhibits epithelial cell proliferation in vitro . The results of Kuramitsu-Fujimoto et al (35) suggest that ameloblastin is the primary bioactive factor of EMD in regards to inhibition of epithelial cell proliferation. It has been suggested that EMPs, such as AMELs and ameloblastin, are required for enamel biomineralization and have synergistic cellular functions (36).…”

Section: Discussionmentioning

confidence: 99%

Effects of enamel matrix proteins on adherence, proliferation and migration of epithelial cells: A real-time in vitro study

Wyganowska‐Świątkowska

Urbaniak

Lipinski

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Enamel matrix derivative (EMD) can mimic odontogenic effects by inducing the proliferation and differentiation of connective tissue progenitor cells, stimulating bone growth and arresting epithelial cells migration. To the best of our knowledge, there is no data indicating that any active component of EMD reduces epithelial cell viability. The present study examines the impact of commercial lyophilized EMD, porcine recombinant amelogenin (prAMEL; 21.3 kDa) and tyrosine-rich amelogenin peptide (TRAP) on the adherence, proliferation and migration of human epithelial cells in real-time. The tongue carcinoma cell line SCC-25 was stimulated with EMD, porcine recombinant AMEL and TRAP, at concentrations of 12.5, 25 and 50 µg/ml. Cell adherence, migration and proliferation were monitored in real-time using the xCELLigence system. No significant effects of EMD on the morphology, adhesion, proliferation and migration of SCC-25 cells were observed. However, porcine recombinant AMEL had a dose-dependent inhibitory effect on SCC-25 cell proliferation and migration. Predominantly, no notable differences were found between control and TRAP-treated cells in terms of cell adhesion and migration, a decrease in proliferation was observed, but this was not statistically significant. EMD and its active components do not increase the tongue cancer cell viability.

show abstract

“…As the process unfolds, weeks after EMD application, bioactive peptides are released around the periodontal defect [10]. EMD contains as well enamelin and ameloblastin [13], the last one being involved in the inhibition of epithelial cell proliferation [14]. Furthermore, the vehicle solution, PGA, has proved to have antimicrobial properties on the bacteria associated with periodontal disease [15].…”

Section: Introductionmentioning

confidence: 99%

The Outcomes of Enamel Matrix Derivative on Periodontal Regeneration under Diabetic Conditions

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Enamel matrix derivative (EMD) is a biomaterial used for periodontal regenerative therapy due to its properties of stimulating cementum development and bone synthesis. Diabetes is a chronic condition that affects healing and predisposes to infection. The aim of this review was to evaluate the current studies available on the application and results of EMD for periodontal regenerative therapy under diabetic conditions. Materials and Methods: Five databases (PubMed, ResearchGate, Scopus, Web of Science and Google Scholar) were searched for relevant articles, using specific keywords in different combinations. The inclusion criteria were clinical trials, case reports, case studies, and animal studies published in English, where periodontal treatment for bone defects includes EMD, and it is performed under diabetic conditions. Results: Of the 310 articles resulted in search, five studies published between 2012 and 2020 met the inclusion criteria and were selected for the current review. In human studies, the use of EMD in infrabony defects showed favorable results at follow-up. In animal studies, periodontal regeneration was reduced in diabetic rats. Conclusions: EMD might promote bone healing when used under diabetic conditions for the regenerative periodontal therapy. Due to limited number of studies, more data are required to sustain the effects of EMD therapy in diabetic settings.

show abstract

Novel biological activity of ameloblastin in enamel matrix derivative

Cited by 4 publications

References 30 publications

An ameloblastin C-terminus variant is present in human adipose tissue

An ameloblastin C-terminus variant is present in human adipose tissue

Effects of enamel matrix proteins on adherence, proliferation and migration of epithelial cells: A real-time in vitro study

The Outcomes of Enamel Matrix Derivative on Periodontal Regeneration under Diabetic Conditions

Contact Info

Product

Resources

About